Home » Posts tagged 'directors'
Tag Archives: directors
Blencowe Resources #BRES – Half-year Report
The Company is pleased to announce its Interim Results for the six-month period to 31 March 2023.
Electronic copies of the report will be available at the Company’s website www.blencoweresourcesplc.com
For further information please contact:
Blencowe Resources Sam Quinn
|
Tel: +44 (0) 1624 681 250 info@blencoweresourcesplc.com
|
Investor Enquiries Sasha Sethi |
Tel: +44 (0) 7891 677 441
|
Tavira Securities Limited Jonathan Evans |
Tel: +44 (0)203 192 1733 jonathan.evans@tavirasecurities.com
|
First Equity Limited Jason Robertson |
Tel: +44 (0)20 7330 1883 |
Interim Management Report
The period to 31 March 2023 (and subsequent events to 30 April 2023) have seen the Company continue to develop its Orom-Cross graphite project.
A Definitive Feasibility Study (“DFS”) commenced and is underway on a number of fronts; this is expected to take around 12 months to complete but the timing is dependent on pre-qualification test work being completed as a means to ultimately deliver binding offtake contracts for the full quantum of graphite concentrate being considered for sale under the phase one operational model. Experienced Australian engineering firm CPC Engineering have agreed to manage and sign off on the DFS, and their experience and involvement will assist greatly in achieving a high quality study and result.
DFS work will concentrate on three key areas. Firstly, work in-country to complete all work necessary to build and operate the mine, including all remaining licenses and permits. The associated infrastructure required to drive the operation will be scrutinised and plans put in place to ensure that all necessary infrastructure will be ready and in place for mining at Orom-Cross. Local studies include management and personnel, mining, equipment, logistics and other key areas. The DFS will take these studies to a far greater extent than the PFS in 2022.
Secondly, pre-qualification testing is taking place in the United States and China to advance the status of Orom-Cross graphite to potential buyers. A bulk sample of 100 tonnes was mined from Orom-Cross in January and (via a special export permit) was approved for transport to China by sea, where it will be put through an existing graphite pilot testing facility. This will save Blencowe substantial time and money by not having to build its own pilot facility on-site to get pre-qualified. The resultant tonnes of 96% concentrate will be then processed to a series of 99.9% products, both expendable’s (large flakes) and SPG (spheronised, purified graphite) (smaller flakes). Assuming successful these samples will be given to end user OEMs to conduct their own testing in their own facilities, to ensure Orom-Cross end product meets their standards and expectations. Once this process is completed then Orom-Cross becomes ‘qualified’ and offtake contract discussions may be entered into.
A 150kg sample was sent to China by air as a preliminary raw material product for the same pilot facility to run tests on how to achieve the best results on the larger sample to follow, and the Company expects feedback on this shortly. This full qualification process is what sets graphite apart from most other metals and it also creates barriers to entry for new participants in the industry. Blencowe is confident that it has the right process/procedures in place to achieve the results it requires to pass this key hurdle. Without binding offtake agreements, it will be difficult to deliver a decision to mine and/or project funding, so this is a critical path item within the DFS. In the past this process has taken other graphite companies several years, Blencowe is hoping that the refinement of this process via its advisors will ensure we ultimately complete this pre-qualification much faster.
In parallel Blencowe is conducting further metallurgical test work in USA to provide evidence (bench-scale testing) that the 96% concentrate it will deliver at Orom-Cross will be suitable for upgrading to the 99.9% end products sought after by the market, and how this us best achieved. These results are expected soon and will be important in ascertaining the end value within the project portfolio.
Thirdly, Blencowe is working through a number of different potential funding options to secure the right partnerships for funding both the DFS and the project implementation. There are different alternatives at both topco and project level and it is important that the right relationships are built that can deliver this project ahead, both now (DFS stage) and in building the full project. Blencowe announced in April its successful passing through a key screening hurdle/test with the Development Finance Corporation (DFC) which is a tier one US Govt-owned financial institution which provides funding solutions for the private sector in areas the US Govt deems are critical. Graphite is considered critical and hence the interaction. This is seen as a valuable relationship for Orom-Cross and the Company is hoping to sign off on a substantial technical assistance grant with the DFC in the near term that will provide up to 50% of the DFS costs. Thereafter this relationship has the potential to offer further funding solutions for the full project finance required. The credibility that association with an institution of this stature brings to both our Company and our project cannot be easily measured; this would be a big result for Blencowe.
These and other DFS activities are the focus and will remain so for the Company ahead. Further capital will be introduced into the Company as and when required, with the continued support of our major shareholders, and once Blencowe delivers the DFC technical assistance grant it is believed that many other funding opportunities will emerge at all levels.
Elsewhere, the Company walked away from the previously announced nickel exploration earn-in deal with SIPA Resources as it was considered more advantageous to concentrate on delivering the Orom-Cross graphite project into production ahead.
Mike Ralston
Chief Executive Officer
Responsibility Statement of the Directors in respect of the Interim Report
The Directors are responsible for preparing the Interim Financial Statements in accordance with applicable law and regulations. In addition, the Directors have elected to prepare the Interim Financial Statements in accordance with International Financial Reporting Standards (“IFRSs”), as adopted by the United Kingdom (“UK”).
The Interim Financial Statements are required to give a true and fair view of the state of affairs of the Group and of the profit or loss of the Group for that period.
In preparing these Interim Financial Statements, the Directors are required to:
· select suitable accounting policies and then apply them consistently;
· present information and make judgements that are reasonable, prudent and provides relevant, comparable and understandable information;
· provide additional disclosures when compliance with the specific requirements in IFRS is insufficient to enable users to understand the impact of particulars transactions, other events and conditions on the entity’s financial position and financial performance; and
· make an assessment of the Group’s ability to continue as a going concern.
The Directors are responsible for keeping proper accounting records that are sufficient to show and explain the Group’s transactions and disclose with reasonable accuracy at any time its financial position of the Group to enable them ensure that the financial statements comply with the requirements of the Companies Act 2006. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Group and to prevent and detect fraud and other irregularities.
The Directors are responsible for the maintenance and integrity of the corporate and Interim Financial Statements. Legislation governing the preparation and dissemination of Interim Financial Statements may differ from one jurisdiction to another.
We confirm that to the best of our knowledge:
· the Interim Financial Statements, prepared in accordance with International Financial Reporting Standards as adopted by the UK, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group for the period;
· the Director’s report includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal risks and uncertainties that they face; and
· the annual report and financial statements, taken as a whole, are fair, balanced and understandable and provide the information necessary for shareholders to assess the group’s performance, business model and strategy.
Consolidated Statement of Comprehensive Income for the six month period ended 31 March 2023
6 months ended 31 Mar 2023 |
6 months ended 31 Mar 2022 |
12 months ended 30 Sep 2022 |
||
(Unaudited) |
(Unaudited) |
(Audited) |
||
Notes |
GBP |
GBP |
GBP |
|
|
|
|
||
Exploration costs |
(16,642) |
(2,744) |
(4,853) |
|
Impairment -Akelikongo project |
– |
– |
(404,533) |
|
Administrative fees and other expenses |
5 |
(446,424) |
(331,617) |
(681,488) |
Adjustments to Liability to surface liability |
– |
– |
51,316 |
|
Operating loss |
|
(463,066) |
(334,361) |
(1,039,558) |
|
|
|
||
Finance costs |
(23,010) |
(21,975) |
(45,916) |
|
Loss before tax |
|
(486,076) |
(356,336) |
(1,085,474) |
|
|
|
||
Income tax |
– |
– |
– |
|
|
|
|
||
Loss after tax |
|
(486,076) |
(356,336) |
(1,085,474) |
|
|
|
|
|
Other comprehensive income |
|
|
|
|
Exchange differences on translation of foreign operation |
|
7,807 |
(2,061) |
(4,205) |
Other comprehensive income, net of tax |
|
7,807 |
(2,061) |
(4,205) |
|
|
|
|
|
Total comprehensive loss |
|
(478,269) |
(358,397) |
(1,089,679) |
|
|
|
|
|
Basic and diluted loss per share (pence) |
9 |
(0.28) |
(0.27) |
(0.68) |
There was no other comprehensive income for the period ended on 31 March 2023.
Consolidated Statement of Financial Position as at 31 March 2023
|
As at 31 Mar 2023 |
As at 31 Mar 2022 |
As at 30 Sept 2022 |
|
|
(Unaudited) |
(Unaudited) |
(Audited) |
|
Notes |
GBP |
GBP |
GBP |
|
|
|
|
|
|
Non-Current Assets |
|
7,065,820 |
5,815,114 |
6,615,253 |
|
|
|
|
|
Current assets |
||||
Trade and other receivables |
6 |
135,901 |
248,413 |
85,847 |
Cash and cash equivalents |
130,740 |
968,693 |
346,994 |
|
Total current assets |
|
266,641 |
1,217,106 |
432,841 |
Total assets |
7,332,461 |
7,032,220 |
7,048,094 |
|
Current liabilities |
||||
Creditors: Amounts falling due within one year |
(429,843) |
(282,217) |
(326,375) |
|
Total current liabilities |
|
(429,843) |
(282,217) |
(326,375) |
Non-current liabilities |
||||
Surface liabilities |
(785,520) |
(924,359) |
(825,852) |
|
Total liabilities |
(1,215,363) |
(1,206,576) |
(1,152,227) |
|
Net assets |
|
6,117,098 |
5,825,644 |
5,897,867 |
Equity |
||||
Share capital |
1,931,316 |
1,101,316 |
1,181,316 |
|
Share premium |
7,428,329 |
6,841,596 |
7,480,829 |
|
Warrants reserves |
402,148 |
317,876 |
402,148 |
|
Translation reserve |
7,264 |
1,601 |
(543) |
|
Retained earnings |
(3,651,959) |
(2,436,745) |
(3,165,883) |
|
Total equity |
|
6,117,098 |
5,825,644 |
5,897,867 |
Consolidated Statement of Changes in Equity for the six month period ended 31 March 2023
|
Share capital |
Share premium |
Share option reserves |
Retained earnings |
Translation reserve |
Total equity |
GBP |
GBP |
GBP |
GBP |
GBP |
GBP |
|
Balance as at 30 Sep 2021 |
901,316 |
5,132,081 |
317,876 |
(2,080,409) |
3,662 |
4,274,526 |
Total comprehensive loss for 6 months |
|
|
|
|
|
|
Loss for the period |
– |
– |
– |
(356,336) |
– |
(356,336) |
Total comprehensive loss |
– |
– |
– |
(356,336) |
– |
(356,336) |
Contributions from equity holders |
||||||
New shares issued |
200,000 |
1,800,000 |
– |
– |
– |
2,000,000 |
Share issue costs |
– |
(90,485) |
– |
– |
– |
(90,485) |
Exchange differences on translation |
– |
– |
– |
– |
(2,061) |
(2,061) |
Total contributions from equity holders |
200,000 |
1,709,515 |
– |
– |
(2,061) |
1,907,454 |
Balance as at 31 Mar 2022 |
1,101,316 |
6,841,596 |
317,876 |
(2,436,745) |
1,601 |
5,825,644 |
Total comprehensive loss for 6 months |
|
|
|
|
|
|
Loss for the period |
– |
– |
– |
(729,138) |
– |
(729,138) |
Total comprehensive loss |
– |
– |
– |
(729,138) |
– |
(729,138) |
Contributions from equity holders |
|
|
|
|
|
|
New shares issued |
80,000 |
720,000 |
– |
– |
– |
800,000 |
Share issue costs |
– |
(80,767) |
– |
– |
– |
(80,767) |
Warrants reserve |
84,272 |
– |
– |
84,272 |
||
Exchange differences on translation of foreign operations |
– |
– |
– |
– |
(2,144) |
(2,144) |
Total contributions from equity holders |
80,000 |
639,233 |
84,272 |
(729,138) |
(2,144) |
801,361 |
|
|
|
|
|
|
|
Balance as at 30 Sep 2022 |
1,181,316 |
7,480,829 |
402,148 |
(3,165,883) |
(543) |
5,897,867 |
Consolidated Statement of Changes in Equity for the six month period ended 31 March 2023
Share capital |
Share premium |
Share option reserves |
Retained earnings |
Translation reserve |
Total equity |
|
|
GBP |
GBP |
GBP |
GBP |
GBP |
GBP |
Balance as at 30 Sep 2022 |
1,181,316 |
7,480,829 |
402,148 |
(3,165,883) |
(543) |
5,897,867 |
|
|
|
|
|
|
|
Total comprehensive loss for 6 months |
||||||
Loss for the period |
– |
– |
– |
(486,076) |
– |
(486,076) |
Total comprehensive loss |
– |
– |
– |
(486,076) |
– |
(486,076) |
Contributions from equity holders |
|
|
|
|
|
|
New shares issued |
750,000 |
– |
– |
– |
– |
750,000 |
Share issued costs |
– |
(52,500) |
– |
– |
– |
(52,500) |
Exchange differences on translation of foreign operations |
– |
– |
– |
– |
7,807 |
7,807 |
Total contributions from equity holders |
750,000 |
(52,500) |
– |
– |
7,807 |
705,307 |
Balance as at 31 Mar 2023 |
1,931,316 |
7,428,329 |
402,148 |
(3,651,959) |
7,264 |
6,117,098 |
Consolidated Statement of Cash Flows for the six month period ended 31 March 2023
As at 31 Mar 2023 |
As at 31 Mar 2022 |
As at 30 Sept 2022 |
||
(Unaudited) |
(Unaudited) |
(Audited) |
||
Notes |
GBP |
GBP |
GBP |
|
Operating activities |
|
|
|
|
Loss after tax |
(486,076) |
(356,336) |
(1,085,474) |
|
Depreciation |
104 |
– |
– |
|
Finance costs |
23,010 |
21,974 |
45,916 |
|
Adjustment to Surface Liability |
– |
– |
(51,316) |
|
Share issue/warrant cost |
– |
– |
84,272 |
|
Impairment – Akelikongo costs |
– |
– |
404,533 |
|
Unrealised currency translation |
261,566 |
(61,217) |
(208,371) |
|
Changes in working capital |
||||
Decrease/(increase) in trade and other receivables |
(50,054) |
(195,833) |
(33,267) |
|
Increase/(decrease) in trade and other payables |
(39,568) |
38,945 |
76,483 |
|
Net cash flows from operating activities |
(291,018) |
(552,467) |
(767,224) |
|
Cash flows from financing activities |
||||
Purchase of fixed assets |
(748) |
– |
– |
|
Investment in exploration assets |
(621,988) |
(481,643) |
(1,423,236) |
|
Net cash flows from investment activities |
(622,736) |
(481,643) |
(1,423,236) |
|
Financing activities |
|
|||
Shares issued |
750,000 |
2,000,000 |
– |
|
Shares issued (cost) |
(52,500) |
(90,486) |
2,444,166 |
|
Net cash flows from financing activities |
697,500 |
1,909,514 |
2,444,166 |
|
Increase in cash and short-term deposits |
(216,254) |
875,404 |
253,706 |
|
Cash and short-term deposits brought forward |
346,994 |
93,288 |
93,288 |
|
Cash and cash equivalents at end of period |
|
130,740 |
968,692 |
346,994 |
Notes to the Financial Statements for the six month period ended 31 March 2023
1. General
Blencowe Resources Plc (the “Company”) is a public limited company incorporated and registered in England and Wales on 18 September 2017 with registered company number 10966847 and its registered office situated in England and Wales at 167-169 Great Portland Street, Fifth Floor, London, England W1W 5PF.
The Group did not earn any trading income during the period under review but incurred expenditure in developing its principal assets.
The Consolidated Interim Financial Statements of the Company for the six month period ended 31 March 2023 comprise the financial statements of the Company and its subsidiaries (together referred to as the “Group”).
2. Accounting Policies
Basis of preparation
The Interim Financial Statements of the Group are unaudited condensed financial statements for the six month period ended 31 March 2023.
The accounting policies applied by the Group in these Interim Financial Statements, are the same as those applied by the Group in its consolidated financial statements and have been prepared on the basis of the accounting policies applied for the financial year to 30 September 2022 which have been prepared in accordance with IFRS as adopted by UK for. The Group Financial Statements have been prepared using the measurement bases specified by IFRS each type of asset, liability, income and expense.
The Group Financial Statements are presented in £, which is the Group’s functional currency. All amounts have been rounded to the nearest pound, unless otherwise stated.
Comparative figures
The comparative figures have been presented as the Group Financial Statements cover the 6 month period ended 31 March 2022 and the 12 month period ended 30 September 2022.
3. Critical accounting estimates and judgments
In preparing the Group’s Interim Financial Statements, the Directors have to make judgments on how to apply the Group’s accounting policies and make estimates about the future. The Directors do not consider there to be any critical judgments that have been made in arriving at the amounts recognised in the Group Financial Statements.
4. Significant accounting policies
The accounting policies adopted are consistent with those followed in the preparation of the annual financial statements of Blencowe Resources Plc for the year ended 30 September 2022. A copy of these financial statements is available on the Group website at https://blencoweresourcesplc.com/
5. Administrative fee and other expenses
|
6 months ended 31 Mar 2023 |
6 months ended 31 Mar 2022 |
12 Months ended 30 Sep 2022 |
|
(Unaudited) |
(Unaudited) |
(Audited) |
|
GBP |
GBP |
GBP |
Directors’ remuneration |
70,023 |
70,046 |
173,413 |
Professional fees |
121,692 |
130,655 |
274,333 |
Salaries |
75,000 |
60,000 |
142,500 |
Listing fees |
18,218 |
19,783 |
26,910 |
Audit fees |
21,644 |
4,375 |
29,000 |
Share issue/warrant cost |
– |
– |
84,272 |
Administration fees |
23,500 |
23,500 |
47,000 |
Broker fees |
20,500 |
29,542 |
38,048 |
Travelling expenses |
7,959 |
– |
34,167 |
Miscellaneous fees |
87,888 |
(6,284) |
(168,155) |
Total |
446,424 |
331,617 |
681,488 |
The Group had two employees who are key management personnel and three Directors. The Directors and the key management personnel’s remuneration related solely to short term employee benefits.
6. Trade and other receivables
|
6 months ended 31 Mar 2023 |
6 months ended 31 Mar 2022 |
12 Months ended 30 Sep 2022 |
|
(Unaudited) |
(Unaudited) |
(Audited) |
|
GBP |
GBP |
GBP |
Other receivables |
21,526 |
37,997 |
24,765 |
Prepayments |
114,375 |
210,416 |
61,082 |
Total |
135,901 |
248,413 |
85,847 |
7. Creditors: Amounts falling due within one year
|
6 months ended 31 Mar 2023 |
6 months ended 31 Mar 2022 |
12 Months ended 30 Sep 2022 |
|
(Unaudited) |
(Unaudited) |
(Audited) |
|
GBP |
GBP |
GBP |
Payables |
118,980 |
268,067 |
140,018 |
Land Owners Liability |
143,036 |
– |
154,403 |
Accruals and provision |
167,827 |
14,150 |
31,954 |
Total |
429,843 |
282,217 |
326,375 |
8. Creditors: Amounts falling after one year
BRUL, the Company’s subsidiary entered into an agreement for surface rights over the land in the mineral area of the licence. The land owners granted BRUL a 49 year lease over an area. The liability to the land owners is to be paid in 8 instalments on at defined dates with the final payment due in 2035.
|
6 months ended 31 Mar 2023 |
6 months ended 31 Mar 2022 |
12 Months ended 30 Sep 2022 |
|
(Unaudited) |
(Unaudited) |
(Audited) |
|
GBP |
GBP |
GBP |
Total payable at the beginning of the period |
978,255 |
887,560 |
887,560 |
Change in estimate |
– |
– |
(51,316) |
Interest charged during the period |
23,010 |
21,975 |
45,916 |
Exchange loss on valuation |
(72,709) |
14,824 |
96,095 |
Total payable as at period end |
928,556 |
924,359 |
978,255 |
|
|
|
|
Analysis between current and non-current liability |
|
|
|
Payable within 12 months |
143,036 |
– |
154,403 |
Payable after 12 months |
785,520 |
924,359 |
823,852 |
|
928,556 |
924,359 |
978,255 |
The value of the lease is measured at the present value of the contractual payments due to the lessor
over the lease term, with the discount rate of 5%.
9. Loss per share
The calculation of the basic and diluted loss per share is based on the following data:
6 months ended 31 Mar 2023 |
6 months ended 31 Mar 2022 |
12 Months ended 30 Sep 2022 |
|
(Unaudited) |
(Unaudited) |
(Audited) |
|
Earnings |
GBP |
GBP |
GBP |
Loss from continuing operations for the period attributable to the equity holders of the Group |
(478,269) |
(353,336) |
(1,085,474) |
Number of shares |
|||
Weighted average number of Ordinary Shares for the purpose of basic and diluted earnings per share |
|||
168,803,923 |
133,655,997 |
160,790,224 |
|
Basic and diluted loss per share (pence) |
(0.28) |
(0.27) |
(0.68) |
There are no potentially dilutive shares in issue.
10. Related party transactions
The are no related party transactions during the period except for the Directors’ remuneration, which have been disclosed in note 5.
Sam Quinn is a director and shareholder of the Company and a Director of Lionshead Consultants Limited. During the period, Lionshead Consultants Limited charged fees for consultancy fees of £18,000 (31 March 2022: £12,000 and 30 Sep 2022: £24,000).
11. Events after the reporting date
On 27 April 2023, the Company announced that it has managed to secure a strategic funding partner for the Orom-cross graphite project. The Development Finance Corporation engaged to fund 50% of the definitive feasibility study costs by way of a technical assistant grant. The DFC is the primary US Government finance institution set up to provide financially sound solutions for private sector initiatives pertaining to critical challenges facing the world.
On 18 May 2023 Blencowe Resources Plc announced that it had raised £635,000 at 5 pence per share through the issue of 12,700,000 new ordinary shares of 0.5p placing shares. The Company will issue investors in the Placing with 1 warrant per 2 Placing Shares (Investor Warrants”) which are exercisable at 8p for a period of 3 years from Admission of the Placing Shares.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
#ORPH Open Orphan – Board appointment
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the appointment of Martin Gouldstone as an Independent Non-Executive Director of the Company with effect from 8 June 2022.Martin will also Chair the Audit & Risk Committee and will be a member of the Nominations Committee and the Remuneration Committee.
Martin brings 30 years of corporate development experience in the CRO, healthcare and pharmaceutical sectors, holding a number of senior roles at healthcare AI businesses. Martin has expertise in executing multi-billion dollar deals across Europe and the US, architecting end-to-end portfolio out-sourcing deals, and negotiating multi-year research partnerships.
Martin is currently Global SVP, Business Development at Owkin, a French-American start-up using artificial intelligence to discover and develop better treatments for unmet medical needs. Previously, Martin has held the roles of Chief Business Officer at both BenevolentAI and Sensyne Health and was a Partner at Results Healthcare, an international M&A advisory firm, where he co-led the company’s healthcare practice. Prior to this, Martin was Head of Life Sciences for BDO UK LLP, Senior Director responsible for M&A and joint venture opportunities in Europe for Quintiles (now IQVIA), and Business Development and Licensing Lead at Confirmant Ltd, Pharmacopeia Inc, Sareum Ltd.
Martin holds a BSc in Genetics and has completed a range of post graduate management courses.
Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan, said: “I am pleased to welcome Martin to the Board of Open Orphan. Martin has extensive corporate development experience in the CRO, healthcare and pharmaceutical sectors and held a number of senior roles in healthcare AI businesses. I look forward to working closely with Martin as we drive further growth across the business.”
Martin Gouldstone, Non-Executive Director, said: “I am delighted to join the Board of Open Orphan at what is an exciting time for the Company and the infectious disease market as it continues to grow significantly post pandemic. I am delighted to bring my previous three decades of experience in the CRO, healthcare and pharmaceutical industry to the Company as it continues to build and expand on partnerships with leading global biopharma companies.”
Regulatory Disclosures
Save for the information set out above and below, there are no further disclosures to be made in accordance with Rule 17, Schedule Two (g) of the AIM Rules for Companies in respect of the appointment of Mr Martin John Gouldstone, aged 55, Martin does not hold an interest in the Company’s share capital.
Current Directorships |
Past Directorships |
Novara Therapeutics Limited |
n.a. |
Orthopaedic Research UK |
|
Sempiternum Ltd |
|
For further information please contact:
Open Orphan plc |
+44 20 7756 1300 |
||
Yamin ‘Mo’ Khan, Chief Executive Officer |
|||
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
Ben Cryer / Edward Mansfield / Phil Walker / Will King |
|||
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
Geoff Nash / James Thompson / Richard Chambers |
|||
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
Anthony Farrell |
|||
Walbrook PR (Financial PR & IR) Paul McManus / Sam Allen / Louis Ashe-Jepson |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0)7980 541 893 / +44 (0) 7502 558 258 / |
||
#ORPH Open Orphan – Appointment of Nominated Adviser and Joint Broker
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that further to the announcements by Arden Partners Plc on 11 and 14 April 2022 regarding the loss of its Nominated Adviser status upon the completion of its recommended takeover, the Company has appointed Liberum Capital Limited (“Liberum”) as its Nominated Adviser and Joint Broker. Given the timing of the completion of the recommended takeover of Arden Partners Plc, the Exchange has agreed that subject to initial due diligence being undertaken, Liberum has until 5pm on 27 July 2022 to complete its full due diligence.
There can be no guarantee on the outcome of the full due diligence and its impact on Liberum’s decision to continue to act as Nominated Adviser. Accordingly, in such circumstances there is a risk that if the Liberum does not continue to act as Nominated Adviser following completion of its full due diligence and the Company has not found an alternative Nominated Adviser, the Company’s AIM securities may be suspended pursuant to AIM Rule 1. If within one month of that suspension, the Company has failed to appoint a replacement Nominated Adviser, the admission of its AIM securities will be cancelled.
Notwithstanding the extension of time provided in respect of completing full due diligence obligations at engagement, Liberum will continue to be subject to all the ongoing Nominated Adviser responsibilities under the AIM Rules for Nominated Advisers.
finnCap plc and Davy will continue to act as the Company’s Joint Brokers.
Yamin ‘Mo’ Khan, Chief Executive Officer at Open Orphan, said: “As the market is aware, Arden Partners can no longer act as Nomad for listed companies from 29 April 2022 and as such, we thank them for their support over the past number of years. We are delighted to now be working with such a prestigious investment bank as Liberum.”
For further information please contact:
Open Orphan plc |
+353 (0) 1 644 0007 |
||
Cathal Friel, Executive Chairman Yamin Khan, Chief Executive Officer |
|
||
|
|
||
Liberum Capital (Nominated Adviser and Joint Broker) |
+44 (0) 20 3100 2000 |
||
Ben Cryer/ Edward Mansfield/ Phil Walker/ Will King |
|
||
|
|
||
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
Geoff Nash / James Thompson / Richard Chambers |
|
||
|
|
||
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
Anthony Farrell |
|
||
|
|
||
Walbrook PR (Financial PR & IR) Paul McManus / Sam Allen / Louis Ashe-Jepson |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com +44 (0)7980 541 893 / +44 (0) 7502 558 258 / +44 (0) 7747 515393 |
||
#BRES Blencowe Resources – Investor Call
Blencowe Resources (BRES:LON), the graphite explorer developing the Orom-Cross jumbo flake graphite project in Uganda, is pleased to announce that it will host a shareholder conference call and Q&A via Zoom conferencing on Thursday 17 February 2022 at 10:00am UK time (6:00pm WST time).
The call will be hosted by Blencowe’s CEO Mike Ralston who will be updating on the recently announced successful drilling results as well as the Company’s strategy moving forward.
Interested investors are invited to register using the following link:
https://us02web.zoom.us/webinar/register/WN_NPAroCXpT6OQIWKP1Xox1Q
Those who wish to may add this event to their online diary by clicking here:
https://www.addevent.com/event/DZ11954380
Shareholders who wish to do so are invited to submit questions via email to info@blencoweresourcesplc.com
The most recent copy of the Company’s corporate presentation can be found at the following link:
https://blencoweresourcesplc.com/presentation/
Please note that until the Q&A session has begun that all participants will initially be muted without audio with the exception of Company management. A recording of the call will also be made available on the Company’s website following the call.
**ENDS**
Contacts
Blencowe Resources Plc
Sam Quinn (London Director)
|
info@blencoweresourcesplc.com +44 (0)1624 681 250
|
Investor Enquiries Sasha Sethi
|
Tel: +44 (0) 7891 677 441 sasha@flowcomms.com
|
Brandon Hill Capital Limited Jonathan Evans
|
Tel: +44 (0)20 3463 5000 jonathan.evans@brandonhillcapital.com |
First Equity Limited Jason Robertson |
Tel: +44 (0)20 7330 1883 jasonrobertson@firstequitylimited.com |